Md Mehedi Hossain, Arfan Khalid, Zaheen Akhter, Sabra Parveen, Mir Owais Ayaz, Aadil Qadir Bhat, Neetu Badesra, Farheen Showket, Mohmmad Saleem Dar, Farhan Ahmed, Sumit Dhiman, Mukesh Kumar, Umed Singh, Razak Hussain, Pankaj Keshari, Ghulam Mustafa, Amit Nargorta, Neha Taneja, Somesh Gupta, Riyaz A Mir, Aravind Singh Kshatri, Utpal Nandi, Nooruddin Khan, P Ramajayan, Govind Yadav, Zabeer Ahmed, Parvinder Pal Singh, Mohd Jamal Dar
JAK-STAT signalling pathway inhibitors have emerged as promising therapeutic agents for the treatment of hair loss. Among different JAK isoforms, JAK3 has become an ideal target for drug discovery because it only regulates a narrow spectrum of γc cytokines. Here, we report the discovery of MJ04, a novel and highly selective 3-pyrimidinylazaindole based JAK3 inhibitor, as a potential hair growth promoter with an IC50 of 2.03 nM. During in vivo efficacy assays, topical application of MJ04 on DHT-challenged AGA and athymic nude mice resulted in early onset of hair regrowth...
April 18, 2024: Journal of Translational Medicine